Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada

In Quebec, Canada, eligibility for palivizumab (PVZ) immunoprophylaxis was expanded in fall 2016 to include healthy-full-term (HFT) infants residing in the circumpolar region of Nunavik and aged <3 months at the start of the RSV season or born during the season. This study assessed the effectiven...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Prev Med Rep
Autores principales: Gilca, Rodica, Billard, Marie-Noëlle, Zafack, Joseline, Papenburg, Jesse, Boucher, François D., Charest, Hugues, Rochette, Marie, De Serres, Gaston
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Regular Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484550/
https://ncbi.nlm.nih.gov/pubmed/32953425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pmedr.2020.101180
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares